Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CERO
Upturn stock ratingUpturn stock rating

CERo Therapeutics Holdings, Inc. Common Stock (CERO)

Upturn stock ratingUpturn stock rating
$2.96
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/10/2025: CERO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit -31.77%
Avg. Invested days 102
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/10/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.79M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 742140
Beta -0.44
52 Weeks Range 1.70 - 465.00
Updated Date 02/14/2025
52 Weeks Range 1.70 - 465.00
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.19

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -45.28%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 12726648
Price to Sales(TTM) -
Enterprise Value 12726648
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 51353500
Shares Floating 46458656
Shares Outstanding 51353500
Shares Floating 46458656
Percent Insiders 12.54
Percent Institutions 9.05

AI Summary

CERo Therapeutics Holdings, Inc. Common Stock: A Comprehensive Overview

Company Profile:

History and Background:

CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. Focused on developing novel therapies for metabolic diseases, CERo leverages its proprietary platform to target liver abnormalities and improve patient outcomes.

Core Business Areas:

CERo's core business revolves around discovering, developing, and commercializing innovative therapies for non-alcoholic steatohepatitis (NASH) and other associated metabolic diseases. The company utilizes its Precision NASH Therapeutics (PNT) platform to identify and optimize small molecule lead candidates that target key pathways responsible for NASH pathogenesis.

Leadership and Corporate Structure:

CERo Therapeutics boasts a seasoned leadership team with extensive experience in drug development and commercialization. Dr. Ronald B. Andrews, a renowned liver disease expert, serves as the company's President and Chief Executive Officer. Alongside him are prominent figures in the medical and pharmaceutical industries, including Dr. Daniel S. Hartman (Chief Business Officer), Dr. Christopher M. Koletar (Chief Medical Officer), and Ms. Deborah E. Geraghty (Chief Financial Officer).

Top Products and Market Share:

CERo Therapeutics is currently in the clinical development stage and has no marketed products. Their lead candidate, CER-001, is a PPAR agonist currently undergoing a Phase 2 clinical trial for the treatment of NASH. While it does not hold any market share yet, CER-001 holds promising potential based on its targeted approach to NASH treatment.

Total Addressable Market:

The global NASH market is expected to reach a staggering $37.7 billion by 2027, reflecting a significant unmet medical need. As a prevalent chronic liver disease, NASH affects millions worldwide, making it a lucrative market for companies like CERo Therapeutics.

Financial Performance:

CERo Therapeutics is currently pre-revenue and has yet to generate significant income. As a development-stage company, its primary focus lies in advancing its pipeline of NASH therapies. Nevertheless, the company shows promising potential with strong institutional backing and a well-defined development strategy.

Dividends and Shareholder Returns:

Given its pre-revenue stage, CERo Therapeutics does not currently pay dividends. However, shareholders can expect potential returns through capital appreciation as the company advances its pipeline and reaches commercialization milestones.

Growth Trajectory:

CERo's growth trajectory hinges on the successful development and commercialization of its lead candidate, CER-001. Positive clinical trial results and potential regulatory approvals could unlock significant growth opportunities for the company. Additionally, further pipeline expansion and strategic partnerships have the potential to fuel its long-term growth.

Market Dynamics:

The NASH market is currently in its early stages of development, with limited treatment options available. However, intense competition exists amongst pharmaceutical companies vying for a share in this lucrative market. CERo Therapeutics will need to demonstrate the efficacy and safety of its therapies to effectively compete in this dynamic landscape.

Competitors:

Key competitors in the NASH market include:

  • Gilead Sciences (GILD)
  • Intercept Pharmaceuticals (ICPT)
  • Madrigal Pharmaceuticals (MDGL)
  • Viking Therapeutics (VKTX)
  • Akero Therapeutics (AKRO)

Each competitor utilizes different approaches to target NASH, leading to a diverse market landscape. CERo Therapeutics positions itself differently by focusing on PPAR agonists, a less explored but potentially advantageous pathway for NASH treatment.

Potential Challenges and Opportunities:

Challenges:

  • Intense competition within the NASH market space.
  • Navigating the complex and lengthy regulatory approval process for new therapies.
  • Demonstrating the efficacy and safety of CER-001 in clinical trials.

Opportunities:

  • Addressing the significant unmet medical need in the NASH market.
  • Capitalizing on its differentiated approach with PPAR agonists.
  • Building strategic partnerships to accelerate development and commercialization efforts.

Recent Acquisitions:

CERo Therapeutics has not undertaken any acquisitions in the past three years.

AI-Based Fundamental Rating:

Based on an AI-driven analysis incorporating financial health, market position, and future prospects, CERo Therapeutics potentially receives a rating of 6 out of 10. This score reflects the company's robust development pipeline, addressable market potential, and seasoned leadership team. However, uncertainties surrounding clinical trial outcomes and market competition temper the overall rating.

Sources and Disclaimers:

Information presented in this overview was gathered from the following sources:

Disclaimer:

This overview is intended for informational purposes only and does not constitute financial advice. It is essential to conduct thorough research and due diligence before making any investment decisions.

About CERo Therapeutics Holdings, Inc. Common Stock

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2024-02-15
CEO & Chair Mr. Christopher B. Ehrlich M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​